Place of antibiotics in the schemes of inflammatory intestinal diseases treatment (review of literature)
- Autores: Golovenko OV1, Korneva TK1, Mikhaylova TL1, A Lyagina I1, Golovenko OV1, Korneva TK1, Michailova TL1, Lyagina IA1
-
Afiliações:
- Edição: Nº 13 (2009)
- Páginas: 11-19
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/277429
- ID: 277429
Citar
Texto integral
Resumo
Sobre autores
O Golovenko
T Korneva
T Mikhaylova
I A Lyagina
O Golovenko
T Korneva
T Michailova
I Lyagina
Bibliografia
- Ардатская М.Д., Минушкин О.Н., Прихно Н.И. и др. Летучие жирные кислоты и их диагностическое и прогностическое значение в гастроэнтерологической практике // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2000. Т. 10. № 5. С. 63-70.
- Бондаренко В.М., Мацулевич Т.В. Дисбактериоз кишечника как клинико-лабораторный синдром. М., 2007.
- Бондаренко В.М., Чуприна Р.П., Воробьева М.А. Механизм действия пробиотических препаратов // Биопрепараты. 2003. № 3. С. 2-5.
- Бондаренко В.М., Воробьев А.А. Дисбиозы и препараты с пробиотической функцией // Журнал микробиологии. 2004. № 1. С. 84-92.
- Бондаренко В.М., Лиходед В.Г., Яковлев М.Ю. Определение эндотоксина грамотрицательных бактерий в крови человека // Журнал микробиологии. 2002. № 2. С. 83-89.
- Вахитов Т.Я., Петров Л.Н., Бондаренко В.М. Концепция пробиотического препарата, содержащего оригинальные микробные метаболиты // Журнал микробиологии. 2005. № 5. С. 108-114.
- Григорьев А.В. Бактериальная гистадгезия // Медичний Всесвiт. 2003. Т. 3. № 2. С. 15-22.
- Ковальчук Л.В., Долгина Е.Н., Ганковская Л.В. и др. Цитокиновый профиль биологических жидкостей организма человека // Аллергология и иммунология. 2005. Т. 6. № 4. С. 460-464.
- Кожевин П.А. Микробные популяции в природе. М., 1989.
- Кононов А.В., Миронова О.Н. Гистобактериоскопический и бактериологический методы исследования колонобиоптатов и характеристика пристеночной микрофлоры, как показатель биоценоза толстой кишки. Пособие для врачей. 2005. С. 12-23.
- Осипов Г.А. Невидимый орган - микрофлора человека. Lu Novellas esteticques. 2004;3:10-15.
- Павлова И.Л., Левченко Е.М. Электронно-микроскопическое исследование адгезивности бактерий. ЖМЭИ. 2002. № 1. С. 1-6.
- Тец В.В., Заславская Н.В. Эффективность действия антибиотиков на бактерий в биопленках // Журнал микробиологии. 2005. № 5. С. 24-26.
- Шендеров Б.А. Медицинская микробная экология и функциональное питание. М., 1998. Т. 2.
- Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000;95:725-29.
- Brandt LJ, Berstein LH, Boley SJ, et al. Metronidazole therapy for perineal Crohn's disease: a follow-up study. Gastroenterology 1982;83:383-87.
- Bamias G, Marini M, Moskaluk CA, et al. Down-regulation of intestinal lymphocyte activation and Th I cytokine production by antibiotic therapy in a murine model of Crohn's disease, J Immunol 2002;169:5308-14.
- Colombel JF, Lemann M, Cassagnou M, et al. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Am J Gastroenterol 1999;94:674-78.
- Camma C, Viscido A, Latella G, et al. Mesalamine in the prevention of clinical and endoscopic post-operative recurrence of Crohn's disease: a meta-analysis. Dig Liver Dis 2002;34:A86.
- Campieri M, Rizzello F, Vcnturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: A randomized controlled study versus mesalazine. Gastroenterology 2000;118(Suppl. 1):A781.
- Dejaco C, Harrer M, Wealthier T, et al. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther 2003;18:1113-1120.
- Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448-55.
- Fukuda M, Kanauchi O, Araki Y, et al. Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. Int J Mol Med 2002;9:65-70.
- Gan SI, Beck PL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol 2003;98:2363-71.
- Gilat T, Leichtman G, Delpre G, et al. A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis. J Clin Gastroenterol 1989;11:392-95.
- Gillis JC, Brogden RN. Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49(3):467-84.
- Gionchetti P, Rizzello F, Morselli C, et al. Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther 2007;25:1231-36.
- Gionchetti P, Rizzcllo F, Ferrieri A, et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: A double-blind, placebo-controlled trial. Dig Dis Sci 1999;44:1220-21.
- Gionchetti P, Rizzcllo F, Venturi A, et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999;13:713-18.
- Greenfield C, Aguilar-Ramirez JR, Pounder RE, et al. Clostridium difficile and inflammatory bowel disease. Gut 1983;24:713-17.
- Guslandi M, Giollo P, Testoni PA. Corticoste-roid-sparing effect of rifaximin, a nonabsorbable oral antibiotic in active ulcerative colitis: Preliminary clinical experience. Curr Ther Res 2004;65:292-96.
- Gillis JC, Brogden RN: Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49:467-84.
- Hoentjen F, Harmstan HJ, Brant H, et al. Antibodies with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in IL-10 deficient mice, Gut 2003;52(12):1721-27.
- Hans W, Scholmerich J, Gross V, et al. The role of the resident intestinal flora in acute and chronic dextran sulfate sodium-induced colitis in mice. Eur J Gastroenterol Hepatol 2000;12:267-73.
- Kallinowski F, Wassmer A, Hofmann MA, et al. Prevalence of enteropathogenic bacteria in surgically treated chronic inflammatory bowel disease. Hepatogastroenterology 1998;45:1552-58.
- Kochhar R, Ayyagari A, Goenka MK, et al. Role of infectious agents in exacerbations of ulcerative colitis in India. A study of Clostridium difficile. J Clin Gastroenterol 1993;16:26-30.
- Konstantinov SR, Fitzsimons N, Vaughan EE, et al. From composition to functionality of the intestinal microbial communities. In: Tannock GW, ed. Probiotics and prebiotics: where are we going? Wymondham, UK: Caister Academic Press 2002:59-84.
- Lukas M, Konecny M, Zboril V. Rifaximin in patients with mild to moderate activity of ulcerative colitis: An open label study. Gastroenterology 2002;122(Suppl. 1):A434.
- Mishkin D, Boston FM, Blank D, et al. The glucose breath test: a diagnostic test for small bowel stricture(s) in Crohn's disease. Dig Dis Sci 2002;47:489-94.
- Mimura T, Rizzello F, Helwig U, et al. Four week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther 2002;16:909-17.
- Neut C, Bulois R Desreumaux P, et at. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 2002;97:939-46.
- Ohkusa T, Nomura T, Terai T, et al. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 2005;40:1334-42.
- Onderdonk AB, HermosJ A, Dzink JL, et al. Protective effect of metronidazole in experimental ulcerative colitis. Gastroenterology 1978;74:521-26.
- Panwala CM, Jones JC, VineyJL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr I a, spontaneously develop colitis. J Immunol 1998;161:5733-44.
- Perencevich M, Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 2006;12:651-64.
- Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328-32.
- Prantera C, Lochs H, Campieri M, et al. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006;23(8):1117-25.
- Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001;69:2277-85.
- Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
- Rutgeerts P, Assche GV, Vermeire S, et al. Ornidazole for prophylaxis of post-operative Crohn's disease: a randomized, double blind, placebocontrolled trial. Gastroenterology 2005;128:856-61.
- Roediger WE, DuncanA, Kapanins Oetal, Reducing sulfur compounds of the colon impair colonocyte nutrition: implications for ulcerative colitis. Gastroenterology 1993;104:802-09.
- Sartor RB. Microbial agents in the pathogenesis, differential diagnosis, and complications of inflammatory bowel diseases. In: Bfaseri MJ, Smith PD, Ravdin JI et al, eds. Infections of the gastrointestinal tract, 2nd edn. Philadelphia: Lippincott Williams & Wilkins 2002:383-413.
- Shafran I, Johnson LK. An open-label evaluation of rifaximin in the treatment of active Crohn's disease. Curr Med Res Opin 2005;21(8):1165-69.
- Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001;7:301-05.
- Shen B, Fazio VW, Remzi FH, et al. Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum 2007;50:498-508.
- Shen B, Remzi FH, Lopez AR, et al. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterology 2008;8:26-33.
- Steinhart AH, Feagan B, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002;123:33-40.
- Stange EF, Travis SPL, Vermeire S, et al. and for the European Crohn's and Colitis Organisation (ECCO). European evidence-based Consensus on the management of Crohn's disease. Gut 2006;55:1-15.
- Sutherland LR, Singleton J, Sessions J, et al. Double-blind, placebocontrolled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-75.
- Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.
- Trnka YM, LaMont JT. Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology 1981;80:693-96.
- Travis SPL, Stange EF, Lemann M, et al. European evidence-based Consensus on the management of ulcerative colitis: Current management. J Crohn's Colitis 2008;2:24-62.
- Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the cooperative Crohn's disease study in Sweden. Gastroenterology 1982;83:550-62.
- Van der Linden PD, Sturkenboom MC, Herings RM, et al. Fluoroquinolones and risk of Achilles tendon disorders: case control study. BMJ 2002;324:1306-07.
- Videla S, Vilaseca J, Guarner F, et al. Role of intestinal microflora in chronic inflammation and ulceration of the rat colon. Gut 1994;35:1090-97.
- Weber R, Koch M, Heizmann WR, et al. Microbic superinfection in relapse of inflammatory bowel disease. J Clin Gastroenterol 1992;14:302-08.
- Yamada T, Deitch E, Specian RD, et al. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993;17:641-62.
- http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2366&mid=1085056570&magid=177